362665-56-3
基本信息
1-[3-[3-(4-氯苯基)丙氧基]丙基]哌啶
Tirolisant
Tiprolisant
Pitolisant (BF2.649)
Tiprolisant Pitolisant
TIPROLISANT
BF-2649
BF 2.649
3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine
Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-
物理化学性质
沸点 | 398.7±32.0 °C(Predicted) |
密度 | 1.056 |
储存条件 | Sealed in dry,Store in freezer, under -20°C |
溶解度 | DMSO |
酸度系数(pKa) | 9.41±0.10(Predicted) |
形态 | 粉末 |
颜色 | Colorless to light yellow |
常见问题列表
发作性睡病(Narcolepsy)是全球公认的罕见病,是一种罕见的睡眠/觉醒障碍疾病,通常被认为是终身性疾病,临床上以日间过度嗜睡(excessivedaytimesleepiness,EDS)、猝倒(cataplexy)、入睡前幻觉、睡眠瘫痪和夜间睡眠紊乱为主要特征,对患者的生活质量、工作或学习能力、以及身心健康往往造成严重的影响。
替洛利生是全球范围内唯一获得发作性睡病适应症,并且同时被美国、欧洲和中国指南推荐的非精神管控类药物。全球上市多年来,替洛利生以出色的安全性和有效性而受到临床的广泛认可。替洛利生在中国的上市意味着结束了我国发作性睡病患者“超说明书”和“红处方”用药为主的困局,为我国患者提供安全、有效和便捷的治疗新选择。
Ki: 0.16 nM (H3 receptor)
EC50: 1.5 nM (H3 receptor)
On the stimulation of guanosine 5′-O-(3-[ 35 S]thio)triphosphate binding to this receptor, Pitolisant (BF2.649) behaves as a competitive antagonist with a K i value of 0.16 nM and as an inverse agonist with an EC 50 value of 1.5 nM and an intrinsic activity ~50% higher than that of ciproxifan. Pitolisant displaces [ 125 I]iodoproxyfan binding from mouse brain cortical membranes with an IC 50 value of 26.4±4.5 nM. Taking into account the K d value of the radioligand (161±9 pM), the deduced K i value for Pitolisant is 14±1 nM. Pitolisant displaces [ 125 I]iodoproxyfan binding from membranes of rat glioma C6 cells stably expressing the human H 3 receptor with an IC 50 value of 4.2±0.2 nM. Taking into account the K d value of the radioligand (50±4 pM), the deduced K i value for Pitolisant is 2.7±0.5 nM. Pitolisant progressively reverses this response with a Hill coefficient close to unity and an IC 50 value of 330±68 nM, leading to a K i value of 17±4 nM. Pitolisant elicits a dose-dependent decrease of the basal-specific [ 35 S]GTPγS binding to membranes with a maximal effect corresponding to 75±1% of the basal-specific binding and an EC 50 value of 1.5±0.1 nM.
The administration of Pitolisantat a single dose of 10 mg/kg 30 min before a single dose of Olanzapine (2 mg/kg b.w.) also significantly affects immobility time in the FST. Subsequent administration of the aforementioned drug sequence in mice statistically significantly increases the duration of immobility in comparison to the time determined in the control group in the FST. It decreased locomotor activity as well. In contrast, the results obtained in subchronic treatment after fifteen administrations of both drugs (Pitolisant 10 mg/kg b.w., and after 30 min Olanzapine 2 mg/kg b.w., and again after 4 h Olanzapine 2 mg/kg b.w.) show that the administration of Pitolisant followed by that of Olanzapine equalized the locomotor activity in mice; in comparison to the level of motility in the control group, to which only Pitolisant is administered. More importantly, this combination of drugs significantly reduces immobility time to the level obtained in the control group in the forced swim test in mice [one-way ANOVA; F (3,20) =4.226,P=0.0181]. Rats given Pitolisant (10 mg/kg) during the conditioning phase stayed 502±94 s on the paired texture, a value not statistically different from that of controls, indicating that Pitolisant did not support place preference.
替洛利生价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-12199 | 替洛利生 Pitolisant | 362665-56-3 | 5mg | 500元 |
2024/11/08 | HY-12199 | 替洛利生 Pitolisant | 362665-56-3 | 10mM * 1mLin DMSO | 550元 |
2024/11/08 | HY-12199 | 替洛利生 Pitolisant | 362665-56-3 | 10mg | 800元 |